Celon PharmaWAR:CLN +0.31%48 Return-on-Tangible-Equity is 149.39% as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 897 Drug Manufacturers companies, Celon Pharma ranks better than 85.06% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Celon Pharma's annualized net income for the quarter that ended in Mar. 2026 was zł650.4 Mil. Celon Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was zł435.4 Mil. Therefore, Celon Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 149.39%.
The historical rank and industry rank for Celon Pharma's Return-on-Tangible-Equity or its related term are showing as below:
WAR:CLN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -19.63 Med: -1.53 Max: 26.47
Current: 26.47
During the past 11 years, Celon Pharma's highest Return-on-Tangible-Equity was 26.47%. The lowest was -19.63%. And the median was -1.53%.
WAR:CLN's Return-on-Tangible-Equity is ranked better than 85.06% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs WAR:CLN: 26.47
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Celon Pharma Return-on-Tangible-Equity Related Terms
Celon Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 149.39% mean?
Celon Pharma (WAR:CLN) has a Return-on-Tangible-Equity of 149.39% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #134 out of 897 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is Celon Pharma's Return-on-Tangible-Equity too high?
Celon Pharma's current Return-on-Tangible-Equity is 149.39%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Celon Pharma's value of 149.39% is 1791% above this industry median. Based on the distribution chart, Celon Pharma ranks #134 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #134 out of 897 companies for Return-on-Tangible-Equity. This places Celon Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Celon Pharma's value of 149.39% is 1791% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Return-on-Tangible-Equity of 149.39% is 1791% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Return-on-Tangible-Equity is 149.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.36, compared to a current price of zł19.70 — trading 15.7% below its estimated fair value. The current Return-on-Tangible-Equity is 149.39% and 1791% above the Drug Manufacturers industry median of 7.90. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Return-on-Tangible-Equity is 149.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.70 is trading 15.7% below its estimated GF Value™ of zł23.36.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
Return-on-Tangible-Equity: 149.39%
GF Value™: zł23.36 vs. price of zł19.70 (15.7% below fair value)
Industry Position: 1791% above the Drug Manufacturers median (#134 of 897)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score
Get the complete analysis for WAR:CLN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
